Nuwellis, Inc. has appointed Mike McCormick as its new Chief Executive Officer, effective June 30, 2026, as part of a strategic leadership transition. John Erb will step down from executive responsibilities but will remain with the company as Chairman of the Board. The announcement was detailed in a Letter to Shareholders reviewing the company's year-to-date performance and outlining future priorities.

Leadership Transition Details

The appointment marks a significant shift in the executive structure of the medical technology company. McCormick, who assumes the role on June 30, 2026, will lead the organization focused on delivering solutions for patients with cardiorenal conditions. Erb's continued presence as Chairman provides stability during the transition period.

Strategic Priorities

The leadership transition accompanies a review of the company's year-to-date performance. Nuwellis remains committed to its core mission in the medical technology sector, specifically targeting cardiorenal conditions. The new CEO is expected to drive the strategic priorities outlined in the shareholder communication.

Nuwellis, Inc. (Nasdaq: NUWE) has appointed Mike McCormick as its new Chief Executive Officer, effective June 30, 2026. John Erb, who currently serves as President, CEO, and Chairman of the Board, will transition from his executive leadership role and continue serving as Chairman of the Board. This leadership change is intended to drive the company's next phase of growth in the cardiorenal care market.

McCormick is a seasoned medical technology executive with more than three decades of leadership experience spanning product development, commercialization, corporate strategy, and value creation. He served as a Board Member and Independent Director of Nuwellis from June 2023 through January 2026. Throughout his career, McCormick has founded, scaled, and led both public and private medical technology companies.

"Mike brings an exceptional combination of operational leadership, commercial expertise, and strategic vision," said Erb. "His deep understanding of the medical device industry and proven track record of building and scaling innovative healthcare companies make him uniquely qualified to lead Nuwellis into its next phase of growth."

McCormick stated that Nuwellis has an important opportunity to expand the role of precision fluid management in cardiorenal care. He aims to build on the company's momentum, strengthen commercial execution, advance the pipeline, and create value for patients, healthcare providers, and shareholders.

Leadership Transition Details

The following table outlines the changes in Nuwellis' executive leadership structure:

About Nuwellis

Nuwellis, Inc. is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis' portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions.